Aminolevulinic acid photodynamic therapy can significantly inhibit the growth of endothelial cells and induce cell apoptosis

doi:10.3969/j.issn.2095-4344.0697

Abstract

Abstract:

BACKGROUND: There is a lack of safe and effective method for hypertrophic scar. Fibroblast hypertrophy, vascular endothelial cell hyperplasia and neovascularization are key points for hypertrophic scar formation. Continuous laser radiation has been shown to induce fibroblast apoptosis. Aminolevulinic acid photodynamic therapy (ALA-PDT) has been extensively applied in the treatment of tumor and skin diseases, which provide novel therapy for hypertrophic scar.
OBJECTIVE: To explore the effect of ALA-PDT on endothelial cell apoptosis.
METHODS: Human umbilical vein endothelial cells were cultured in vitro, and divided into four groups: control group (no treatment), single-drug group (incubation with 2 mmol/L 5-aminolevulinic acid), single-light group (3 J/cm2 photodynamic irradiation for 8 minutes) and ALA-PDT group (after incubation with 2 mmol/L 5-aminolevulinic acid for 4 hours, irradiated by 3 J/cm2 photodynamic for 8 minutes, and cultured for 24 hours in dark).
RESULTS AND CONCLUSION: Fluorescence microscopy showed that the accumulation of fluorescence in umbilical vein endothelial cells was ALA-dependent and peaked at a concentration of 2 mmol/L. Cytotoxicity test showed no significant difference in cell viability in the simple-drug group. Cell viability in the ALA-PDT group was significantly inhibited at a drug concentration of 2 and 4 mmol/L (P < 0.01). Hoechst 33258 staining and flow cytometry analysis showed that ALA-PDT could induce cell apoptosis when ALA concentration was 2 mmol/L (P < 0.01). These results indicate that ALA-PDT can significantly inhibit the growth of endothelial cells and induce apoptosis of endothelial cells.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Cicatrix, Apoptosis, Endothelial Cells

CLC Number:

R318

Ge Wenjia, Ma Xiaorong, Ouyang Tianxiang . Aminolevulinic acid photodynamic therapy can significantly inhibit the growth of endothelial cells and induce cell apoptosis[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(36): 5840-5845.

Figures/Tables 2

References

[1] Ehrlich HP, Desmouliere A, Diegelmann RF, et al. Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol. 1994;145:105-113.

[2] Fujita AK, Rodrigues PG, Requena MB, et al. Fluorescence evaluations for porphyrin formation during topical PDT using ALA and methyl-ALA mixtures in pig skin models. Photodiagnosis Photodyn Ther. 2016;15:236-244.

[3] Chun Q, Zhiyong W, Fei S, et al. Dynamic biological changes in fibroblasts during hypertrophic scar formation and regression. Int Wound J. 2016;13:257-262.

[4] Zhang Z, Chen Y, Ding J, et al. Biocompatible 5-Aminolevulinic Acid/Au Nanoparticle-Loaded Ethosomal Vesicles for In Vitro Transdermal Synergistic Photodynamic/ Photothermal Therapy of Hypertrophic Scars. Nanoscale Res Lett. 2017;12:622.

[5] Wang XQ, Liu YK, Qing C, et al. A review of the effectiveness of antimitotic drug injections for hypertrophic scars and keloids. Ann Plast Surg. 2009;63:688-692.

[6] Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med 2011;17:113-125.

[7] Stylli SS, Howes M, MacGregor L, et al. Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome. J Clin Neurosci. 2004;11:584-596

[8] O'Connell KA, Okhovat JP, Zeitouni NC. Photodynamic Therapy for Bowen's Disease (Squamous Cell Carcinoma in situ) Current Review and Update. Photodiagnosis Photodyn Ther. 2018. DOI:10. 1016/j.pdpdt.2018.09.009.

[9] van der Veer WM, Niessen FB, Ferreira JA, et al. Time course of the angiogenic response during normotrophic and hypertrophic scar formation in humans. Wound Repair Regen. 2011;19:292-301.

[10] Chen B, Pogue BW, Luna JM, et al. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. Clin Cancer Res. 2006;12:917-923.

[11] Peng Q, Berg K, Moan J, et al. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol. 1997;65:235-251.

[12] Cohen DK and Lee PK. Photodynamic Therapy for Non-Melanoma Skin Cancers. Cancers (Basel). 2016. DOI:10. 1016/j. pdpdt.2018.09.009.

[13] Wennberg AM, Stenquist B, Stockfleth E, et al. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. Transplantation. 2008;86:423-429.

[14] Jarvi MT, Niedre MJ, Patterson MS, et al. Singlet oxygen luminescence dosimetry (SOLD) for photodynamic therapy: current status, challenges and future prospects. Photochem Photobiol. 2006; 82:1198-1210.

[15] Chang M, Ma X, Ouyang T, et al. Potential molecular mechanisms involved in 5-aminolevulinic acid-based photodynamic therapy against human hypertrophic scars. Plast Reconstr Surg. 2015;136:715-727.

[16] Kwak DH, Bae TH, Kim WS, et al. Anti-vascular endothelial growth factor (bevacizumab) therapy reduces hypertrophic scar formation in a rabbit ear wounding model. Arch Plast Surg. 2016;43:491-497.

[17] Ge X, Zhao L, He L, et al. Vascular endothelial growth factor receptor 2 (VEGFR2, Flk-1/KDR) protects HEK293 cells against CoCl(2) -induced hypoxic toxicity. Cell Biochem Funct. 2012;30:151-157.

[18] Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006;155:1262-1269.

[19] Lian N, Li T. Growth factor pathways in hypertrophic scars: Molecular pathogenesis and therapeutic implications. Biomed Pharmacother. 2016;84:42-50.

[20] Armour A, Scott PG and Tredget EE. Cellular and molecular pathology of HTS: basis for treatment. Wound Repair Regen. 2007;15 Suppl 1:S6-S17.

[21] Hembry RM and Ehrlich HP. Immunolocalization of collagenase and tissue inhibitor of metalloproteinases (TIMP) in hypertrophic scar tissue. Br J Dermatol. 1986;115:409-420.

[22] Cao PF, Xu YB, Tang JM, et al. HOXA9 regulates angiogenesis in human hypertrophic scars: induction of VEGF secretion by epidermal stem cells. Int J Clin Exp Pathol. 2014; 7:2998-3007.

[23] Bruscino N, Rossi R, Dindelli M, et al. Therapeutic Hotline: Facial skin rejuvenation in a patient treated with photodynamic therapy for actinic keratosis. Dermatol Ther. 2010;23:86-89.

[24] Bruscino N, Lotti T and Rossi R. Photodynamic therapy for a hypertrophic scarring: a promising choice. Photodermatol Photoimmunol Photomed. 2011;27:334-335.

[25] Landes R, Illanes A, Goeppner D, et al. A study of concentration changes of Protoporphyrin IX and Coproporphyrin III in mixed samples mimicking conditions inside cancer cells for Photodynamic Therapy. PLoS One. 2018;13:e0202349.

[26] Coupienne I, Fettweis G, Rubio N, et al. 5-ALA-PDT induces RIP3-dependent necrosis in glioblastoma. Photochem Photobiol Sci. 2011;10:1868-1878.

[27] Yang X, Palasuberniam P, Kraus D, et al. Aminolevulinic acid-based tumor detection and therapy: molecular mechanisms and strategies for enhancement. Int J Mol Sci. 2015;16:25865-25880.

[28] Zhang Z, Chen Y, Xu H, et al. 5-Aminolevulinic acid loaded ethosomal vesicles with high entrapment efficiency for in vitro topical transdermal delivery and photodynamic therapy of hypertrophic scars. Nanoscale 2016;8:19270-19279.

[29] Fujino M, Nishio Y, Ito H, et al. 5-Aminolevulinic acid regulates the inflammatory response and alloimmune reaction. Int Immunopharmacol. 2016;37:71-78.

[30] da Luz Dias R, Basso B, Donadio MVF, et al. Leucine reduces the proliferation of MC3T3-E1 cells through DNA damage and cell senescence. Toxicol In Vitro. 2018;48:1-10.